Pathway Capital Management LP Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Pathway Capital Management LP bought a new stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 98,329 shares of the company's stock, valued at approximately $6,243,000. Verona Pharma PLC American Depositary Share accounts for about 36.0% of Pathway Capital Management LP's portfolio, making the stock its 2nd biggest position. Pathway Capital Management LP owned 0.12% of Verona Pharma PLC American Depositary Share at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. RTW Investments LP acquired a new position in Verona Pharma PLC American Depositary Share during the fourth quarter valued at approximately $84,568,000. Wellington Management Group LLP grew its stake in shares of Verona Pharma PLC American Depositary Share by 61.0% during the 4th quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after acquiring an additional 1,146,609 shares during the period. Darwin Global Management Ltd. bought a new position in shares of Verona Pharma PLC American Depositary Share in the fourth quarter worth $37,637,000. Point72 Asset Management L.P. bought a new stake in Verona Pharma PLC American Depositary Share during the fourth quarter worth about $33,019,000. Finally, Janus Henderson Group PLC increased its stake in Verona Pharma PLC American Depositary Share by 59.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock worth $77,466,000 after purchasing an additional 624,370 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Performance

VRNA remained flat at $104.90 during midday trading on Monday. The company's stock had a trading volume of 2,726,328 shares, compared to its average volume of 1,727,039. Verona Pharma PLC American Depositary Share has a 1 year low of $18.51 and a 1 year high of $105.30. The stock has a 50 day moving average of $87.55 and a two-hundred day moving average of $70.00. The company has a market cap of $8.93 billion, a P/E ratio of -52.45 and a beta of 0.24. The company has a debt-to-equity ratio of 1.07, a quick ratio of 8.73 and a current ratio of 8.86.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million. As a group, sell-side analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other Verona Pharma PLC American Depositary Share news, General Counsel Andrew Fisher sold 80,000 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $11.53, for a total value of $922,400.00. Following the completion of the transaction, the general counsel owned 359,999 shares in the company, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David Zaccardelli sold 400,000 shares of the company's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the completion of the transaction, the chief executive officer owned 13,190,168 shares of the company's stock, valued at $150,367,915.20. This represents a 2.94% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,965,800 shares of company stock worth $20,056,881. Company insiders own 4.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on VRNA. Cowen cut Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a report on Wednesday, July 9th. Wolfe Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. TD Cowen downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Cantor Fitzgerald lifted their price target on Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. Finally, HC Wainwright restated a "neutral" rating and issued a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a report on Monday, July 14th. Eleven analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.